New York, Jan 18, 2026, 10:37 EST — Market closed.
- Johnson & Johnson shares last closed down about 0.4% on Friday.
- A holiday-shortened week puts the focus on J&J’s quarterly results and 2026 outlook.
- Health care stocks were among the weaker S&P 500 sectors into the long weekend.
Johnson & Johnson shares slipped 0.4% to $218.66 on Friday, the last session before U.S. markets shut for the Martin Luther King Jr. Day holiday. Yahoo Finance
The stock heads into the week with investors leaning hard on earnings to justify valuations. “The most important thing right now is earnings,” said Chris Fasciano, chief market strategist at Commonwealth Financial Network. Reuters
On Friday, U.S. stocks ended nearly flat in choppy trade, while the S&P 500 health care sector fell 0.8%, a bigger drop than the broader market. “We’re at the start of the earnings season,” said Anthony Saglimbene, chief market strategist at Ameriprise Financial. Reuters
The NYSE is closed on Monday for the holiday, leaving investors to position for a compressed week when trading resumes on Tuesday. New York Stock Exchange
Johnson & Johnson is due to report fourth-quarter results on Wednesday, Jan. 21, and host an earnings call at 8:30 a.m. ET. Johnson Johnson Investor Relations
For J&J, the set-up is familiar. Traders will be watching whether its drug portfolio can keep offsetting pricing pressure and competition, and whether medical device demand holds up as hospitals and surgeons manage budgets.
The company’s moves tracked a softer day for big health care names into the long weekend. Abbott fell 1.43% on Friday, Merck dropped 1.93% and Pfizer slid 0.93%, while J&J fell 0.41%, according to MarketWatch data. MarketWatch
Outside J&J’s core businesses, investors have also been watching the fate of former consumer unit Kenvue. Proxy adviser ISS recommended shareholders back Kimberly-Clark’s plan to buy Kenvue, writing: “On balance, support for the transaction is warranted.” Reuters
But the clean story can still get messy fast. A cautious 2026 outlook, an unexpected hit to a key franchise, or fresh legal costs could pull attention away from the steadier parts of the model and put the stock back in the market’s risk bucket.
What matters next is Wednesday’s report and the tone of the call — especially any shift in full-year expectations and how management frames demand in both pharmaceuticals and devices.
